StockData
Vor Biopharma Inc. logo

Vor Biopharma Inc. (VOR) stock

VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$17.83−0.35 (-1.93%)

Close on Nov 18, 2026Market cap $1.10BP/E –Yield –

Vor Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vor Biopharma's free cash flow for the twelve months ending Sep 30, 2026 was -$119.68M. For fiscal 2025 it was -$143.65M. The highest annual figure on record is -$40.45M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$143.65M–
FY2024Dec 31, 2024-$99.89M–
FY2023Dec 31, 2023-$101.36M–
FY2022Dec 31, 2022-$93.61M–
FY2021Dec 31, 2021-$73.04M–
FY2020Dec 31, 2020-$40.45M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$32.77M–
Q2 FY2026Jun 30, 2026-$25.50M–
Q1 FY2026Mar 31, 2026-$38.29M–
Q4 FY2025Dec 31, 2025-$23.12M–
Q3 FY2025Sep 30, 2025-$53.91M–
Q2 FY2025Jun 30, 2025-$35.34M–
Q1 FY2025Mar 31, 2025-$31.30M–
Q4 FY2024Dec 31, 2024-$24.14M–
Q3 FY2024Sep 30, 2024-$23.32M–
Q2 FY2024Jun 30, 2024-$21.86M–
Q1 FY2024Mar 31, 2024-$30.58M–
Q4 FY2023Dec 31, 2023-$24.14M–
Q3 FY2023Sep 30, 2023-$28.36M–
Q2 FY2023Jun 30, 2023-$24.50M–
Q1 FY2023Mar 31, 2023-$24.36M–
Q4 FY2022Dec 31, 2022-$18.67M–
Q3 FY2022Sep 30, 2022-$19.20M–
Q2 FY2022Jun 30, 2022-$30.82M–
Q1 FY2022Mar 31, 2022-$24.92M–
Q4 FY2021Dec 31, 2021-$18.76M–
Q3 FY2021Sep 30, 2021-$17.98M–
Q2 FY2021Jun 30, 2021-$17.48M–
Q1 FY2021Mar 31, 2021-$18.82M–
Q4 FY2020Dec 31, 2020-$15.11M–
Q3 FY2020Sep 30, 2020-$9.83M–
Q2 FY2020Jun 30, 2020-$8.88M–
Q1 FY2020Mar 31, 2020-$6.63M–

More Vor Biopharma figures

See a number that looks wrong?